Debnarayan DuttaMD, PhD, MBBS
Dr Debnarayan Dutta is the Senior Consultant & Head of the Department of Radiation Onclogy at Amrita Institute of Medical Sciences, Cochin. He is a reputed radiation oncologist, working in Apollo Cancer Hospital Chennai as a senior consultant before joining Amrita. He did his MBBS from National Medical College, Kolkata in the year 1999 and did MD in radiation oncology from the Nilratan Sirkar Medical College, Kolkata from 2003 to 2006. After completing his MD training, he joined Tata Memorial Hospital, Mumbai as neurooncology & stereotactic radiosurgery fellow in 2006. Then he did a fellowship in IMRT in head & neck radiation oncology from Tata Memorial Hospital, Mumbai.
He was trained at Tata Memorial Hospital after post-graduation for almost 4 years, from 2006 till 2010. He joined Apollo Cancer Hospital Chennai in 2010 as a consultant and was an integral part of CyberKnife treatment team. He was awarded the prestigious ‘MERIT’ award for being a promising cancer researcher by the American Society of Clinical Oncology (ASCO) in 2008, the presenter in ‘Hosino’ young investigator award at Yokohama Japan 2009, awarded ‘Neucletron Fellowship’ in 2010.
He received aboard training from Antoine Lacassagne Cancer Centre, Nice and Oscar Lambart Cancer Centre, Lille, France for CyberKnife. He had a short stint at Munich CyberKnife Centre, Munich. He is one of the first few Cyberknife users in India and regarded as an expert in radiosurgery & SBRT. He received training from Varian SBRT training centre at Lisbon, Portugal in 2013 and was part of IBA proton users meeting at Paris in 2014. He is an eminent speaker in radiosurgery and neurooncology, with more than 100 national and international presentations in different academic forums. He has 35 indexed publications, 30 indexed abstracts, three chapters in three books and is a reviewer of few indexed journals. He is persuading his academic interest as a PhD student in Vellore Institute of Technology (VIT). His thesis is on the molecular prognostication of head & neck cancer.